Introduction
Alzheimer's disease (AD) is a debilitating neurodegenerative disease characterized by intraneuronal neurofibrillary tangles, mostly composed of abnormally phosphorylated tau (Iqbal and Grundke-Iqbal, 2006 ) and extracellular senile plaques, largely composed of Aβ peptide (Hyman and Gomez-Isla, 1997) . Several therapeutic strategies have been developed to eliminate excessive Aβ. Active immunization of transgenic mice with Aβ peptides reduced amyloid burden (Schenk et al., 1999) and partially restored behavioral deficits (Janus et al., 2000; Morgan et al., 2000) . These experiments led to a clinical trial with active immunization using synthetic Aβ42. However, the clinical trial was discontinued due to meningoencephalitis in 6% of cases without a clear relation to serum anti-Aβ titers (Orgogozo et al., 2003) . It seems that an excessive T cell response to the vaccine and microglia activation may have been responsible for the observed inflammation, and these effects should be considered for a safer anti-Aβ immunotherapy for AD (Orgogozo et al., 2003) . Other approaches that are less likely to result in autoimmune reactions have been directed towards passive immunization (Morgan, 2006b), and anti-Aβ antibodies can reduce soluble and insoluble Aβ deposits (Bacskai et al., 2001) as well as restore behavioral deficits in transgenic mice (Kotilinek et al., 2002) .
Microglia seem to play a key role in Aβ clearance although the underlying mechanisms have not been completely elucidated. Activated microglia cells are found in AD patients and transgenic mouse models, and they are strategically located in close proximity to senile plaques (Bacskai et al., 2001; Stalder et al., 1999) . It has also been shown that Aβ itself provokes activation of microglia and astrocytes (Monsonego and Weiner, 2003) . Antibody-induced Aβ clearance in vitro may be mediated by cellular removal of the deposits through Fc receptor-mediated phagocytosis (Bard et al., 2000) . However, this route of removal is not necessary since antibody-mediated amyloid clearance can occur in the absence of Fc receptor activation, suggesting that multiple mechanisms of amyloid clearance are likely (Bacskai et al., 2002a; Das et al., 2003; Wilcock et al., 2003) . Following this idea, it is also possible that antibody-Aβ interaction leads to disaggregation of deposits, and a small fraction of the plaques could be either removed passively with other cerebrospinal fluid components or made available for phagocytosis and clearance by microglia without receptor stimulation. It also needs to be taken into account that the possible beneficial effect of microglia activation in Aβ removal may be counterbalanced by the negative effect of an increased secretion of inflammatory mediators that are potentially toxic to the nearby neurons (Rogers et al., 2002) . In this sense, the therapeutic goal would be to suppress the neurodegenerative phenotypes of
